Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches [version 1; referees: 2 approved]
Cancer drug discoverers and developers are blessed and cursed with a plethora of drug targets in the tumor cells themselves and the surrounding stromal elements. This bounty of targets has, at least in part, inspired the rapid increase in the number of clinically available small-molecule, biological...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2018-03-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/7-308/v1 |